Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs …
